RSS   Newsletter   Contact   Advertise with us

Roche attempt to retool arthritis drug for coronavirus pneumonia fails trial

Christian Fernsby ▼ | July 29, 2020
Roche announced that the phase III Covacta study of Actemra RoActemra tocilizumab did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe coronavirus associated pneumonia.
Roche
Study   Roche
In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra RoActemra.

Topics: Roche

The Covacta study did not identify any new safety signals for Actemra RoActemra.

Further analysis of the trial results is needed to fully understand the data.

The results will be submitted for publication in a peer-reviewed journal.


 

MORE INSIDE POST